AbbVie

Apr 04, 2017

Biogen triumphs in latest Tecfidera patent dispute Biogen has prevailed in a patent squabble with Denmark’s Forward Pharma over multiple sclerosis med Tecfidera—but the decision may not actually help the Big Biotech steer clear of generic rivals. The Patent Trial and Appeal Board (PTAB) ruled Friday that Forward cou...

Oct 04, 2016

FDA Approves Janssen's STELARA for the Treatment of Adults With Moderately to Severely Active Crohn’s Disease Janssen Biotech Inc. received approval from the U.S. FDA for STELARA (ustekinumab), used for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older). The drug is for the ...

Aug 24, 2016

Partnership between Bristol Meyers Squibb and AbbVie aims to evaluate the Combination of Rova-T plus Opdivo and Opdivo plus Yervoy Regimen Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed extensive-stage small cell lung cancer...

Jul 25, 2014

The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of t...